1. Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: NAME OF PRESENTER: Curtis Triplitt, PharmD, CDE Speaker’s Bureau: Amylin, Eli Lilly, Novartis, Takeda Board Member/Advisory Panel: Amylin, Eli Lilly

2. Treating Type 2 DM in the 21 st Century Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Asst. Professor, Dept. of Medicine/ Div. of Diabetes Clinical Assistant Professor of Pharmacy University of Texas Health Science Center San Antonio, Texas

3. Presentation not available due to pending publication and intellectual property issues.

4. The following references were used: Pathophysiologic Basis of Treatment: Adapted from Inzucchi SE. JAMA. 2002;287:360-372 Factors that Influence the Efficiency of Inhaled Insulin: Nature Reviews Drug Discovery 1; 529-540 (2002) Exubera Inhaled Insulin Change-Baseline FEV1 in T1DM: September 8, 2005, EMDAC Meeting, Food and Drug Administration Exubera Inhaled Insulin Change-Baseline DLCO in Type 1 DM - Pooled Phase 2 and 3 Studies: September 8, 2005, EMDAC Meeting, Food and Drug Administration Technosphere/MannKind Insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA (R) Inhaler: Diabetes Technology and Therapeutics 2002;4(5):589 Technosphere/MannKind Inhaled Insulin: Rosenstock J.et al. ADA Scientific Sessions. 2005, San Diego, CA: 357-OR When Does Beta-Cell Function Decline? Ferrannini, E. et al. J Clin Endocrinol Metab 2005;90:493-500 Initial Combination Therapy With Sitagliptin Plus Metformin Study: Design-Data available on request from Merck & Co., Inc. Please specify 20752930(1)-JAN. Initial Combination Therapy With Sitagliptin Plus Metformin Study: A1C Results Through 104 Wks (2 years): 1. Goldstein BJ et al. Diabetes Care. 2007;30(8):1979–1987. 2. Data available on request from Merck & Co., Inc. Please specify 20752930(1)-JAN. Study Results: Placebo-subtracted HbA 1c Reductions in Combination Therapy Studies- Williams-Herman D, et al. Abstract 875. Presented at the 19th World Diabetes Congress, 3–7 December 2006, Cape Town, South Africa. Liraglutide’s Impact on Glucagon Secretion inType 2 Diabetes Mellitus- Degn KB, et al. Diabetes 2004, 53:1187-1194 Exenatide BID versus Exenatide QW- Drucker D, Buse JB, Taylor K et al. DURATION-1 trial online Lancet Sept 8 2008 DOI:10.1016/S0140-6736(08)61206-4 A1C: 52-Week Evaluable Population-A1C: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco,CA. FPG: 52-Week Evaluable Population-FPG: 52-Week Evaluable Population- Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. Weight Loss Through Week 52-Weight Loss Through Week 52-Buse J et al. Extenatide once weekly elicits sustained glycemic controls and weight loss over 52 weeks. Presented at: the 68th Annual Meeting of the American Diabetes Association; June 6-10, 2008; San Francisco, CA. Type 2 DM: Pancreatitis-1. Frey et al. Pancreas 2006. 33(4): 336-344.2. Martinez et al. Pancreatology 2006;6:206-209 Liraglutide and Calcitonin-http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf Thiazolidinediones- Nature Medicine 2005;11:861-866 Limb Fractures in Women with Rosiglitazone- J of Endocrinology 2004;183:203-16; Nature Medicine 2007;13:1496-1503